• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, March 28, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

New research aims to combat prion-like spread of Tau pathology in Alzheimer’s

Bioengineer by Bioengineer
October 28, 2020
in Health
Reading Time: 4 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Manipulation of heparan sulfate may thwart prion-like spread of Tau pathology

IMAGE

Credit: Rensselaer Polytechnic Institute

TROY, N.Y. — Tangles of misfolded tau proteins in the brain are closely associated with memory loss in patients with Alzheimer’s disease. In order for this tau pathology to spread, the protein must interact with heparan sulfate, a sugar molecule found on the surface of neurons.

Armed with evidence that a specific site — known as the 3-O-sulfate group — on heparan sulfate is critical to the transfer, a research program funded by the NIH’s National Institute of Aging is scrutinizing the interactions between heparan sulfate and tau, determining how misfolded tau spreads in the brain, and developing strategies to block it.

“Understanding how tau is moving from cell to cell will give us a clear target for research and drug development,” said Chunyu Wang, a professor of biological sciences at Rensselaer Polytechnic Institute and a member of the Rensselaer Center for Biotechnology and Interdisciplinary Studies. “Our prior research has shown that the 3-O-sulfate group on heparan sulfate facilitates the spread of tau pathology, but we need further characterization of tau-heparan sulfate interaction at the molecular level, and evidence from animal models and human tissue.”

Wang and his team, which includes Rensselaer glycobiology expert Robert Linhardt, were awarded a four-year $2.6 million grant to pursue a research program examining the tau-glycan interactions at the molecular, cellular, and whole organism level.

“There is a strong correlation between the spread of misfolded tau and the progression of Alzheimer’s disease, and here we have a promising point of potential therapeutic intervention if we gain a strong fundamental understanding of this interaction,” said Curt Breneman, dean of the Rensselaer School of Science. “It’s an elegant approach and promising research.”

Tau is an abundant protein in neurons. In contrast to most proteins, tau is flexible and dynamic, enabling it to interact with many proteins in the neuron and carry out multiple functions.

In neurons, the most important function of normal tau proteins — of which there are actually six variants — is to build the cell’s version of an intracellular highway by bundling microtubules together into causeways for transporting all manner of cellular goods, such as vesicles carrying neurotransmitters. But if misfolded, tau proteins clump together inside neurons, forming neurofibrillary tangles that ultimately kill the neurons.

The presence of neurofibrillary tangles inside the brain of Alzheimer’s patients is closely correlated with memory loss, and the extent of neurofibrillary tangles is used as a way of determining the stage of the disease.

More perniciously, misfolded tau spreads like a prion, a form of infectious disease that is spread without a virus or bacterial pathogen. Once misfolded tau appears inside the brain, it spreads progressively through neuronal connections.

To move between neurons, the first neuron secretes tau into a synapse, where it binds to heparan sulfate on the surface of the recipient neuron, which mediates the tau uptake into the recipient neuron. However, how the tau and heparan sulfate interact with each other is not well understood on many levels.

In research published last year in Angewandte Chemie, a team that included Wang and Linhardt showed that the 3-O-sulfate group on the sugar rings of heparan sulfate plays a critical role in moving tau proteins from one neuron to another. The presence of sulfate groups at the 3-O- position is rare compared to other sites on the sugar ring, and according to the paper, tau is only the seventh known protein that recognizes 3-O-sulfation for binding. But their research, using nuclear magnetic resonance spectroscopy, surface plasmon resonance spectroscopy, glycan array, and cell cultures, showed that 3-O-sulfation of heparan sulfate enhances tau binding, and that both binding and cellular uptake can be reduced with specific changes by reducing the level of 3-O sulfation on heparan sulfate.

“Although 3-O-sulfation is very rare, it’s important for biological function,” Wang said. “This is something that we discovered late last year and this work forms the basis for further mechanistic study, and drug discovery. For example, enzymes that carry out 3-O-sulfation may be targeted in Alzheimer’s drug discovery.”

At the molecular level, the researchers will study the interactions between purified tau and heparan sulfate, generating 3-D pictures of how the two molecules interact. On the cellular level, they will use fluorescent labeled tau and observe how it is taken into neurons, and the effects of drug candidates. And mice genetically engineered to produce heparan sulfate without 3-O sulfation will allow them to test if and how tau pathology can spread in the absence of the 3-O sulfate group.

###

Wang and Linhardt are joined in the research by Jian Liu at the University of North Carolina Chapel Hill and Lianchun Wang of the University of Southern Florida.

About Rensselaer Polytechnic Institute

Founded in 1824, Rensselaer Polytechnic Institute is America’s first technological research university. Rensselaer encompasses five schools, 32 research centers, more than 145 academic programs, and a dynamic community made up of more than 7,900 students and over 100,000 living alumni. Rensselaer faculty and alumni include more than 145 National Academy members, six members of the National Inventors Hall of Fame, six National Medal of Technology winners, five National Medal of Science winners, and a Nobel Prize winner in Physics. With nearly 200 years of experience advancing scientific and technological knowledge, Rensselaer remains focused on addressing global challenges with a spirit of ingenuity and collaboration. To learn more, please visit http://www.rpi.edu.

Media Contact
Mary Martialay
[email protected]

Original Source

https://news.rpi.edu/content/2020/10/28/new-research-aims-combat-prion-spread-tau-pathology-alzheimer%E2%80%99s

Tags: AlzheimerBiochemistryBiotechnologyMedicine/Healthneurobiology
Share13Tweet8Share2ShareShareShare2

Related Posts

Cutaneous Lesion Location: Key to Head Injury Risk?

March 27, 2026

Aversive Learning Hijacks Brain Sugar Sensor

March 25, 2026

Can Psychosocial Factors Influence Cancer Risk?

March 23, 2026

Depression Factors in Elderly: Pre vs. Post-COVID Analysis

March 23, 2026
Please login to join discussion

POPULAR NEWS

  • blank

    Revolutionary AI Model Enhances Precision in Detecting Food Contamination

    96 shares
    Share 38 Tweet 24
  • Imagine a Social Media Feed That Challenges Your Views Instead of Reinforcing Them

    1004 shares
    Share 397 Tweet 248
  • Uncovering Functions of Cavernous Malformation Proteins in Organoids

    54 shares
    Share 22 Tweet 14
  • Promising Outcomes from First Clinical Trials of Gene Regulation in Epilepsy

    51 shares
    Share 20 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

In-Sensor Cryptography Links Physical Process to Digital Identity

Can Psychosocial Factors Influence Cancer Risk?

Depression Factors in Elderly: Pre vs. Post-COVID Analysis

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 78 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.